Publications from OUS - Metastasis - biology and therapy

164 publications found

Publications 2020

1. Barkovskaya A, Seip K, Prasmickaite L, Mills IG, Moestue SA, Itkonen HM (2020)
   Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells
   Sci Rep, 10 (1), 16992
   DOI 10.1038/s41598-020-74083-z, PubMed 33046784
2. Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2020)
   Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
   Mol Ther (in press)
   DOI 10.1016/j.ymthe.2020.11.019, PubMed 33212301
3. Flem-Karlsen K, Nyakas M, Farstad IN, McFadden E, Wernhoff P, Jacobsen KD, Flørenes VA, Mælandsmo GM (2020)
   Soluble AXL as a marker of disease progression and survival in melanoma
   PLoS One, 15 (1), e0227187
   DOI 10.1371/journal.pone.0227187, PubMed 31917795
4. Halvorsen AR, Haugen MH, Öjlert ÅK, Lund-Iversen M, Jørgensen L, Solberg S, Mælandsmo GM, Brustugun OT, Helland Å (2020)
   Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
   Front Oncol, 10, 590755
   DOI 10.3389/fonc.2020.590755, PubMed 33324562
5. Juraleviciute M, Pozniak J, Nsengimana J, Harland M, Randerson-Moor J, Wernhoff P, Bassarova A, Oy GF, Troen G, Florenes VA, Bishop DT, Herlyn M, Newton-Bishop J, Slipicevic A (2020)
   MX 2 is a novel regulator of cell cycle in melanoma cells
   Pigment Cell Melanoma Res., 33 (3), 446-457
6. Knutsen E, Lellahi SM, Aure MR, Nord S, Fismen S, Larsen KB, Gabriel MT, Hedberg A, Bjørklund SS, Oslo Breast Cancer Research Consortium (OSBREAC), Bofin AM, Mælandsmo GM, Sørlie T, Mortensen ES, Perander M (2020)
   The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers
   Sci Rep, 10 (1), 1277
   DOI 10.1038/s41598-020-57759-4, PubMed 31992741
7. Lavelle TJ, Alver TN, Heintz KM, Wernhoff P, Nygaard V, Nakken S, Øy GF, Bøe SL, Urbanucci A, Hovig E (2020)
   Dysregulation of MITF Leads to Transformation in MC1R-Defective Melanocytes
   Cancers (Basel), 12 (7)
   DOI 10.3390/cancers12071719, PubMed 32605315
8. Lien VT, Kristiansen MK, Pettersen S, Haugen MH, Krauss S, Olberg DE, Waaler J, Klaveness J (2020)
   Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation (vol 9, pg 37092, 2019)
   RSC Adv., 10 (9), 4927
9. Pandya AD, Øverbye A, Sahariah P, Gaware VS, Høgset H, Masson M, Høgset A, Mælandsmo GM, Skotland T, Sandvig K, Iversen TG (2020)
   Drug-Loaded Photosensitizer-Chitosan Nanoparticles for Combinatorial Chemo- and Photodynamic-Therapy of Cancer
   Biomacromolecules, 21 (4), 1489-1498
   DOI 10.1021/acs.biomac.0c00061, PubMed 32092254
10. Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
    Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
    Acta Oncol, 59 (7), 733-740
    DOI 10.1080/0284186X.2020.1742377, PubMed 32208873
11. Steinhaeuser SS, Morera E, Budkova Z, Schepsky A, Wang Q, Rolfsson O, Riedel A, Krueger A, Hilmarsdottir B, Maelandsmo GM, Valdimarsdottir B, Sigurdardottir AK, Agnarsson BA, Jonasson JG, Ingthorsson S, Traustadottir GA, Oskarsson T, Gudjonsson T (2020)
    ECM1 secreted by HER2-overexpressing breast cancer cells promotes formation of a vascular niche accelerating cancer cell migration and invasion
    Lab Invest, 100 (7), 928-944
    DOI 10.1038/s41374-020-0415-6, PubMed 32203150
12. Torgersen ML, Judge PJ, Bada Juarez JF, Pandya AD, Fusser M, Davies CW, Maciejewska MK, Yin DJ, Maelandsmo GM, Skotland T, Watts A, Sandvig K (2020)
    Physicochemical Characterization, Toxicity and In Vivo Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin
    J Biomed Nanotechnol, 16 (4), 419-431
    DOI 10.1166/jbn.2020.2911, PubMed 32970975

Publications 2019

1. Andersson Y, Inderberg EM, Kvalheim G, Herud TM, Engebraaten O, Flatmark K, Dueland S, Fodstad Ø (2019)
   Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
   Acta Oncol, 59 (4), 404-409
   DOI 10.1080/0284186X.2019.1704864, PubMed 31876430
2. Barkovskaya A, Seip K, Hilmarsdottir B, Maelandsmo GM, Moestue SA, Itkonen HM (2019)
   O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
   Sci Rep, 9 (1), 5670
   DOI 10.1038/s41598-019-42153-6, PubMed 30952976
3. Camilio KA, Wang MY, Mauseth B, Waagene S, Kvalheim G, Rekdal Ø, Sveinbjørnsson B, Mælandsmo GM (2019)
   Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
   Breast Cancer Res, 21 (1), 9
   DOI 10.1186/s13058-018-1092-x, PubMed 30670061
4. Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
   Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
   J Proteome Res, 18 (10), 3649-3660
   DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662
5. Flem-Karlsen K, McFadden E, Omar N, Haugen MH, Øy GF, Ryder T, Gullestad HP, Hermann R, Mælandsmo GM, Flørenes VA (2019)
   Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
   Mol Cancer Ther, 19 (3), 895-905
   DOI 10.1158/1535-7163.MCT-19-0290, PubMed 31871265
6. Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
   p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
   Sci Rep, 9 (1), 5839
   DOI 10.1038/s41598-019-42303-w, PubMed 30967582
7. Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
   A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
   Transl Oncol, 12 (7), 951-958
   DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111
8. Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
   Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
   Breast Cancer Res, 21 (1), 61
   DOI 10.1186/s13058-019-1141-0, PubMed 31088535
9. Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
   Breast cancer quantitative proteome and proteogenomic landscape
   Nat Commun, 10 (1), 1600
   DOI 10.1038/s41467-019-09018-y, PubMed 30962452
10. Juraleviciute M, Pozniak J, Nsengimana J, Harland M, Randerson-Moor J, Wernhoff P, Bassarova A, Øy GF, Trøen G, Flørenes VA, Bishop DT, Herlyn M, Newton-Bishop J, Slipicevic A (2019)
    MX 2 is a novel regulator of cell cycle in melanoma cells
    Pigment Cell Melanoma Res, 33 (3), 446-457
    DOI 10.1111/pcmr.12837, PubMed 31660681
11. Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
    Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
    Cancer Res, 79 (16), 4293-4304
    DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201
12. Lien VT, Kristiansen MK, Pettersen S, Haugen MH, Olberg DE, Waaler J, Klaveness J (2019)
    Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation
    RSC Adv., 9 (63), 37092-37100
13. Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
    Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
    Arch Pharm (Weinheim), 352 (9), e1900101
    DOI 10.1002/ardp.201900101, PubMed 31414521
14. Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
    miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
    Mol Oncol, 13 (10), 2278-2296
    DOI 10.1002/1878-0261.12561, PubMed 31402562
15. Nome ME, Euceda LR, Jabeen S, Debik J, Bathen TF, Giskeødegård GF, Taskén KA, Maelandsmo GM, Halvorsen B, Yndestad A, Borgen E, Garred Ø, Aukrust P, Ueland T, Engebraaten O, Kristensen VN, Tekpli X (2019)
    Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
    Int J Cancer, 146 (1), 223-235
    DOI 10.1002/ijc.32638, PubMed 31444972
16. Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
    Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
    Clin Exp Immunol, 197 (1), 74-82
    DOI 10.1111/cei.13283, PubMed 30821848
17. Pandya AD, Jäger E, Bagheri Fam S, Höcherl A, Jäger A, Sincari V, Nyström B, Štěpánek P, Skotland T, Sandvig K, Hrubý M, Mælandsmo GM (2019)
    Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
    Int J Nanomedicine, 14, 6269-6285
    DOI 10.2147/IJN.S208938, PubMed 31496685
18. Pitman KE, Bakke KM, Kristian A, Malinen E (2019)
    Ultra-early changes in vascular parameters from dynamic contrast enhanced MRI of breast cancer xenografts following systemic therapy with doxorubicin and liver X receptor agonist
    Cancer Imaging, 19 (1), 88
    DOI 10.1186/s40644-019-0280-y, PubMed 31856923
19. Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
    Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
    Cancer Immunol Res, 7 (5), 701-706
    DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006
20. Saeednejad Zanjani L, Madjd Z, Rasti A, Asgari M, Abolhasani M, Tam KJ, Roudi R, Mælandsmo GM, Fodstad Ø, Andersson Y (2019)
    Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics
    Front Oncol, 9, 1302
    DOI 10.3389/fonc.2019.01302, PubMed 31921617

Publications 2018

1. Berg J, Halvorsen AR, Bengtson MB, Taskén KA, Mælandsmo GM, Yndestad A, Halvorsen B, Brustugun OT, Aukrust P, Ueland T, Helland Å (2018)
   Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
   BMC Cancer, 18 (1), 739
   DOI 10.1186/s12885-018-4659-0, PubMed 30005623
2. Eng MS, Kaur J, Prasmickaite L, Engesæter BØ, Weyergang A, Skarpen E, Berg K, Rosenblum MG, Mælandsmo GM, Høgset A, Ferrone S, Selbo PK (2018)
   Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins
   Photochem Photobiol Sci, 17 (5), 539-551
   DOI 10.1039/C7PP00358G, PubMed 29565434
3. Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2018)
   Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
   J Control Release, 293, 183-192
   DOI 10.1016/j.jconrel.2018.11.029, PubMed 30529259
4. Prasmickaite L, Tenstad EM, Pettersen S, Jabeen S, Egeland EV, Nord S, Pandya A, Haugen MH, Kristensen VN, Børresen-Dale AL, Oslo Breast Cancer Research Consortium (OSBREAC), Engebråten O, Maelandsmo GM (2018)
   Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4
   Mol Oncol, 12 (9), 1540-1558
   DOI 10.1002/1878-0261.12319, PubMed 29741811
5. Seip K, Jørgensen K, Haselager MV, Albrecht M, Haugen MH, Egeland EV, Lucarelli P, Engebraaten O, Sauter T, Mælandsmo GM, Prasmickaite L (2018)
   Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment
   Cancer Lett, 439, 1-13
   DOI 10.1016/j.canlet.2018.09.023, PubMed 30240588

Publications 2017

1. Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E et al. (2017)
   Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome
   Breast Cancer Res, 19 (1), 44
   DOI 10.1186/s13058-017-0812-y, PubMed 28356166
2. Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E et al. (2017)
   Interrogating open issues in cancer precision medicine with patient-derived xenografts
   Nat Rev Cancer, 17 (4), 254-268
   DOI 10.1038/nrc.2016.140, PubMed 28104906
3. Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E et al. (2017)
   Interrogating open issues in cancer medicine with patient-derived xenografts
   Nat Rev Cancer, 17 (10), 632 (in press)
   DOI 10.1038/nrc.2017.85, PubMed 28912576
4. Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T, Oslo Breast Cancer Consortium (OSBREAC), Naume B, Borgen E, Mælandsmo GM (2017)
   Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer
   Breast Cancer Res Treat, 162 (1), 127-137
   DOI 10.1007/s10549-016-4096-1, PubMed 28058579
5. Euceda LR, Haukaas TH, Giskeodegard GF, Vettukattil R, Engel J, Silwal-Pandit L, Lundgren S, Borgen E, Garred O, Postma G, Buydens LMC, Borresen-Dale AL, Engebraaten O, Bathen TF (2017)
   Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy
   Metabolomics, 13 (4), 37
6. Halldorsson S, Rohatgi N, Magnusdottir M, Choudhary KS, Gudjonsson T, Knutsen E, Barkovskaya A, Hilmarsdottir B, Perander M, Mælandsmo GM, Gudmundsson S, Rolfsson Ó (2017)
   Metabolic re-wiring of isogenic breast epithelial cell lines following epithelial to mesenchymal transition
   Cancer Lett, 396, 117-129
   DOI 10.1016/j.canlet.2017.03.019, PubMed 28323032
7. Hilmarsdottir B, Briem E, Halldorsson S, Kricker J, Ingthorsson S, Gustafsdottir S, Mælandsmo GM, Magnusson MK, Gudjonsson T (2017)
   Inhibition of PTP1B disrupts cell-cell adhesion and induces anoikis in breast epithelial cells
   Cell Death Dis, 8 (5), e2769
   DOI 10.1038/cddis.2017.177, PubMed 28492548
8. Jernström S, Hongisto V, Leivonen SK, Due EU, Tadele DS, Edgren H, Kallioniemi O, Perälä M, Mælandsmo GM, Sahlberg KK (2017)
   Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
   Breast Cancer (Dove Med Press), 9, 185-198
   DOI 10.2147/BCTT.S115600, PubMed 28356768
9. Kristian A, Holtedahl JE, Torheim T, Futsaether C, Hernes E, Engebraaten O, Mælandsmo GM, Malinen E (2017)
   Dynamic 2-Deoxy-2-[¹⁸F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts
   Mol Imaging Biol, 19 (2), 271-279
   DOI 10.1007/s11307-016-0998-x, PubMed 27541026
10. Lunde NN, Haugen MH, Bodin Larsen KB, Damgaard I, Pettersen SJ, Kasem R, Rut W, Drag M, Poreba M, Johansen HT, Solberg R (2017)
    Glycosylation is important for legumain localization and processing to active forms but not for cystatin E/M inhibitory functions
    Biochimie, 139, 27-37
    DOI 10.1016/j.biochi.2017.05.009, PubMed 28528272
11. Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K (2017)
    Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases
    Oncotarget, 8 (44), 76290-76304
    DOI 10.18632/oncotarget.19350, PubMed 29100312
12. Øverbye A, Holsæter AM, Markus F, Škalko-Basnet N, Iversen TG, Torgersen ML, Sønstevold T, Engebraaten O, Flatmark K, Mælandsmo GM, Skotland T, Sandvig K (2017)
    Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide
    Oncotarget, 8 (44), 76921-76934
    DOI 10.18632/oncotarget.20217, PubMed 29100358
13. Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
    Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
    ESMO Open, 2 (2), e000158
    DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
14. Saldova R, Haakensen VD, Rødland E, Walsh I, Stöckmann H, Engebraaten O, Børresen-Dale AL, Rudd PM (2017)
    Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up
    Mol Oncol, 11 (10), 1361-1379
    DOI 10.1002/1878-0261.12105, PubMed 28657165

Publications 2016

1. Alver TN, Lavelle TJ, Longva AS, Øy GF, Hovig E, Bøe SL (2016)
   MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma
   Oncotarget, 7 (34), 55128-55140
   DOI 10.18632/oncotarget.10422, PubMed 27391157
2. Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K (2016)
   Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy
   Cancer Med, 5 (8), 1840-9
   DOI 10.1002/cam4.766, PubMed 27273130
3. Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA (2016)
   Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism
   Oncotarget, 7 (2), 1878-94
   DOI 10.18632/oncotarget.6479, PubMed 26646591
4. Dahl JA, Jung I, Aanes H, Greggains GD, Manaf A, Lerdrup M, Li G, Kuan S, Li B, Lee AY, Preissl S, Jermstad I, Haugen MH, Suganthan R, Bjørås M, Hansen K, Dalen KT, Fedorcsak P, Ren B, Klungland A (2016)
   Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition
   Nature, 537 (7621), 548-552
   DOI 10.1038/nature19360, PubMed 27626377
5. Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K (2016)
   Expression and clinical significance of Wee1 in colorectal cancer
   Tumour Biol, 37 (9), 12133-12140
   DOI 10.1007/s13277-016-5081-3, PubMed 27220319
6. Evensen L, Johansen PL, Koster G, Zhu K, Herfindal L, Speth M, Fenaroli F, Hildahl J, Bagherifam S, Tulotta C, Prasmickaite L, Mælandsmo GM, Snaar-Jagalska E, Griffiths G (2016)
   Zebrafish as a model system for characterization of nanoparticles against cancer
   Nanoscale, 8 (2), 862-77
   DOI 10.1039/c5nr07289a, PubMed 26648525
7. Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K (2016)
   Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases
   Clin Exp Metastasis, 34 (1), 51-62
   DOI 10.1007/s10585-016-9829-3, PubMed 27812769
8. Fleten KG, Flørenes VA, Prasmickaite L, Hill O, Sykora J, Mælandsmo GM, Engesæter B (2016)
   hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
   Cell Death Discov, 2, 16081
   DOI 10.1038/cddiscovery.2016.81, PubMed 28028438
9. Hetland G, Eide DM, Tangen JM, Haugen MH, Mirlashari MR, Paulsen JE (2016)
   The Agaricus blazei-Based Mushroom Extract, Andosan™, Protects against Intestinal Tumorigenesis in the A/J Min/+ Mouse
   PLoS One, 11 (12), e0167754
   DOI 10.1371/journal.pone.0167754, PubMed 28002446
10. Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H (2016)
    Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
    Br J Cancer, 115 (8), 929-939
    DOI 10.1038/bjc.2016.278, PubMed 27599042
11. Kim E, Kim J, Maelandsmo GM, Johansen B, Moestue SA (2016)
    Anti-angiogenic therapy affects the relationship between tumor vascular structure and function: A correlation study between micro-computed tomography angiography and dynamic contrast enhanced MRI
    Magn Reson Med, 78 (4), 1513-1522
    DOI 10.1002/mrm.26547, PubMed 27888545
12. Kim E, Tunset HM, Cebulla J, Vettukattil R, Helgesen H, Feuerherm AJ, Engebråten O, Mælandsmo GM, Johansen B, Moestue SA (2016)
    Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model
    BMC Cancer, 16, 191
    DOI 10.1186/s12885-016-2225-1, PubMed 26951085
13. Lindstad T, Qu S, Sikkeland J, Jin Y, Kristian A, Mælandsmo GM, Collas P, Saatcioglu F (2016)
    STAMP2 is required for human adipose-derived stem cell differentiation and adipocyte-facilitated prostate cancer growth in vivo
    Oncotarget, 8 (54), 91817-91827
    DOI 10.18632/oncotarget.11131, PubMed 29190878
14. Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad Ø (2016)
    Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
    Oncotarget, 7 (6), 6891-901
    DOI 10.18632/oncotarget.6902, PubMed 26771843
15. Rud AK, Boye K, Fodstad Ø, Juell S, Jørgensen LH, Solberg S, Helland Å, Brustugun OT, Mælandsmo GM (2016)
    Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
    Diagn Pathol, 11 (1), 50
    DOI 10.1186/s13000-016-0504-4, PubMed 27316334
16. Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L (2016)
    Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
    Oncotarget, 7 (15), 19997-20015
    DOI 10.18632/oncotarget.7671, PubMed 26918352
17. Westrøm S, Bønsdorff TB, Abbas N, Bruland ØS, Jonasdottir TJ, Mælandsmo GM, Larsen RH (2016)
    Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma
    PLoS One, 11 (10), e0165382
    DOI 10.1371/journal.pone.0165382, PubMed 27776176

Publications 2015

1. Almåsbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G, Kyte JA (2015)
   Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
   Gene Ther, 22 (5), 391-403
   DOI 10.1038/gt.2015.4, PubMed 25652098
2. Andersson Y, Engebraaten O, Juell S, Aamdal S, Brunsvig P, Fodstad Ø, Dueland S (2015)
   Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
   Br J Cancer, 113 (11), 1548-55
   DOI 10.1038/bjc.2015.380, PubMed 26554649
3. Bettum IJ, Gorad SS, Barkovskaya A, Pettersen S, Moestue SA, Vasiliauskaite K, Tenstad E, Øyjord T, Risa Ø, Nygaard V, Mælandsmo GM, Prasmickaite L (2015)
   Metabolic reprogramming supports the invasive phenotype in malignant melanoma
   Cancer Lett, 366 (1), 71-83
   DOI 10.1016/j.canlet.2015.06.006, PubMed 26095603
4. Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM (2015)
   Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes
   Clin Exp Metastasis, 32 (8), 755-67
   DOI 10.1007/s10585-015-9742-1, PubMed 26349943
5. Ingthorsson S, Andersen K, Hilmarsdottir B, Maelandsmo GM, Magnusson MK, Gudjonsson T (2015)
   HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR
   Oncogene, 35 (32), 4244-55
   DOI 10.1038/onc.2015.489, PubMed 26686087
6. Jin Y, Wang L, Qu S, Sheng X, Kristian A, Mælandsmo GM, Pällmann N, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Fazli L, Rennie P, Risberg B, Wæhre H, Danielsen HE, Ozpolat B, Saatcioglu F (2015)
   STAMP2 increases oxidative stress and is critical for prostate cancer
   EMBO Mol Med, 7 (3), 315-31
   DOI 10.15252/emmm.201404181, PubMed 25680860
7. Magnussen GI, Emilsen E, Giller Fleten K, Engesæter B, Nähse-Kumpf V, Fjær R, Slipicevic A, Flørenes VA (2015)
   Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
   BMC Cancer, 15, 462
   DOI 10.1186/s12885-015-1474-8, PubMed 26054341
8. Pitman KE, Rusten E, Kristian A, Malinen E (2015)
   Variability of dynamic 18F-FDG-PET data in breast cancer xenografts
   Acta Oncol, 54 (9), 1399-407
   DOI 10.3109/0284186X.2015.1062140, PubMed 26217987
9. Prasmickaite L, Berge G, Bettum IJ, Aamdal S, Hansson J, Bastholt L, Øijordsbakken M, Boye K, Mælandsmo GM (2015)
   Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial
   Cancer Immunol Immunother, 64 (6), 769-76
   DOI 10.1007/s00262-015-1686-4, PubMed 25832001
10. Rizos E, Siafakas N, Katsantoni E, Skourti E, Salpeas V, Rizos I, Tsoporis JN, Kastania A, Filippopoulou A, Xiros N, Margaritis D, Parker TG, Papageorgiou C, Zoumpourlis V (2015)
    Correction: Let-7, Mir-98 and Mir-181 as Biomarkers for Cancer and Schizophrenia
    PLoS One, 10 (8), e0135863
    DOI 10.1371/journal.pone.0135863, PubMed 26266816
11. Skrbo N, Tenstad E, Mælandsmo GM, Sørlie T, Andersen K (2015)
    From autonomy to community; new perspectives on tumorigenicity and therapy resistance
    Cancer Treat Rev, 41 (10), 809-13
    DOI 10.1016/j.ctrv.2015.10.004, PubMed 26519005
12. Tamhane T, Lllukkumbura R, Lu S, Maelandsmo GM, Haugen MH, Brix K (2015)
    Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cells
    Biochimie, 122, 208-18
    DOI 10.1016/j.biochi.2015.09.003, PubMed 26343556
13. Tamhane T, Wolters BK, Illukkumbura R, Maelandsmo GM, Haugen MH, Brix K (2015)
    Construction of a plasmid coding for green fluorescent protein tagged cathepsin L and data on expression in colorectal carcinoma cells
    Data Brief, 5, 468-75
    DOI 10.1016/j.dib.2015.09.022, PubMed 26594658

Publications 2014

1. Grinde MT, Skrbo N, Moestue SA, Rødland EA, Borgan E, Kristian A, Sitter B, Bathen TF, Børresen-Dale AL, Mælandsmo GM, Engebraaten O, Sørlie T, Marangoni E, Gribbestad IS (2014)
   Interplay of choline metabolites and genes in patient-derived breast cancer xenografts
   Breast Cancer Res, 16 (1), R5
   DOI 10.1186/bcr3597, PubMed 24447408
2. Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K (2014)
   High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting
   Eur J Cancer, 51 (1), 9-17
   DOI 10.1016/j.ejca.2014.10.020, PubMed 25466510
3. Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A (2014)
   Patient-derived xenograft models: an emerging platform for translational cancer research
   Cancer Discov, 4 (9), 998-1013
   DOI 10.1158/2159-8290.CD-14-0001, PubMed 25185190
4. Kristian A, Riss P, Qu H, Milde M, Schoultz BW, Engebraaten O, Mælandsmo GM, Malinen E (2014)
   Positron emission tomography and pharmacokinetics of 2-[18F]-fluoroethyl choline for metabolic studies in breast cancer xenografts
   Acta Oncol, 53 (8), 1086-92
   DOI 10.3109/0284186X.2014.934398, PubMed 25017377
5. Momtazi L, Bagherifam S, Singh G, Hofgaard A, Hakkarainen M, Glomm WR, Roos N, Mælandsmo GM, Griffiths G, Nyström B (2014)
   Synthesis, characterization, and cellular uptake of magnetic nanocarriers for cancer drug delivery
   J Colloid Interface Sci, 433, 76-85
   DOI 10.1016/j.jcis.2014.07.013, PubMed 25112915
6. Nygaard V, Prasmickaite L, Vasiliauskaite K, Clancy T, Hovig E (2014)
   Melanoma brain colonization involves the emergence of a brain-adaptive phenotype
   Oncoscience, 1 (1), 82-94
   DOI 10.18632/oncoscience.11, PubMed 25593989
7. Skrbo N, Hjortland GO, Kristian A, Holm R, Nord S, Prasmickaite L, Engebraaten O, Mælandsmo GM, Sørlie T, Andersen K (2014)
   Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft
   PLoS One, 9 (11), e113278
   DOI 10.1371/journal.pone.0113278, PubMed 25419568

Publications 2013

1. Bettum IJ, Vasiliauskaite K, Nygaard V, Clancy T, Pettersen SJ, Tenstad E, Mælandsmo GM, Prasmickaite L (2013)
   Metastasis-associated protein S100A4 induces a network of inflammatory cytokines that activate stromal cells to acquire pro-tumorigenic properties
   Cancer Lett, 344 (1), 28-39
   DOI 10.1016/j.canlet.2013.10.036, PubMed 24215866
2. Engebraaten O, Vollan HKM, Børresen-Dale AL (2013)
   Triple-negative breast cancer and the need for new therapeutic targets
   Am J Pathol, 183 (4), 1064-1074
   DOI 10.1016/j.ajpath.2013.05.033, PubMed 23920327
3. Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, Maelandsmo GM (2013)
   Nuclear legumain activity in colorectal cancer
   PLoS One, 8 (1), e52980
   DOI 10.1371/journal.pone.0052980, PubMed 23326369
4. Kristian A, Nilsen LB, Røe K, Revheim ME, Engebråten O, Mælandsmo GM, Holm R, Malinen E, Seierstad T (2013)
   Dynamic (18) F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts
   Nucl Med Mol Imaging, 47 (3), 173-80
   DOI 10.1007/s13139-013-0211-y, PubMed 24900104
5. Kristian A, Revheim ME, Qu H, Mælandsmo GM, Engebråten O, Seierstad T, Malinen E (2013)
   Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts
   Acta Oncol, 52 (7), 1566-72
   DOI 10.3109/0284186X.2013.813634, PubMed 23984812
6. Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mælandsmo GM, Engebraaten O (2013)
   Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations
   Clin Cancer Res, 20 (2), 404-12
   DOI 10.1158/1078-0432.CCR-13-1865, PubMed 24192926
7. Moestue SA, Dam CG, Gorad SS, Kristian A, Bofin A, Mælandsmo GM, Engebråten O, Gribbestad IS, Bjørkøy G (2013)
   Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer
   Breast Cancer Res, 15 (1), R16
   DOI 10.1186/bcr3391, PubMed 23448424
8. Rud AK, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K (2013)
   Clinical significance of disseminated tumour cells in non-small cell lung cancer
   Br J Cancer, 109 (5), 1264-70
   DOI 10.1038/bjc.2013.450, PubMed 23942067

Publications 2012

1. Boye K, Nesland JM, Sandstad B, Haugland Haugen M, Mælandsmo GM, Flatmark K (2012)
   EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
   Br J Cancer, 107 (4), 667-74
   DOI 10.1038/bjc.2012.293, PubMed 22782346
2. Engesæter B, Engebraaten O, Flørenes VA, Mælandsmo GM (2012)
   Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma
   PLoS One, 7 (9), e45492
   DOI 10.1371/journal.pone.0045492, PubMed 23029050
3. Ree AH (2012)
   Individualised treatment of metastatic cancer
   Tidsskr Nor Laegeforen, 132 (21), 2358-9
   DOI 10.4045/tidsskr.12.1130, PubMed 23160572
4. Schee K, Flatmark K, Holm R, Boye K, Paus E (2012)
   Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients (vol 33, pg 73, 2012)
   Tumor Biol., 33 (4), 1263-1264

Publications 2011

1. Berge G, Pettersen S, Grotterød I, Bettum IJ, Boye K, Mælandsmo GM (2011)
   Osteopontin--an important downstream effector of S100A4-mediated invasion and metastasis
   Int J Cancer, 129 (4), 780-90
   DOI 10.1002/ijc.25735, PubMed 20957651
2. Engesæter BO, Sathermugathevan M, Hellenes T, Engebråten O, Holm R, Flørenes VA, Mælandsmo GM (2011)
   Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells
   Cancer Biol Ther, 12 (1), 47-58
   DOI 10.4161/cbt.12.1.15714, PubMed 21508672
3. Flatmark K, Borgen E, Nesland JM, Rasmussen H, Johannessen HO, Bukholm I, Rosales R, Hårklau L, Jacobsen HJ, Sandstad B, Boye K, Fodstad Ø (2011)
   Disseminated tumour cells as a prognostic biomarker in colorectal cancer
   Br J Cancer, 104 (9), 1434-9
   DOI 10.1038/bjc.2011.97, PubMed 21448171

Publications 2010

1. Berge G, Andersen K, Haugen MH, Maelandsmo GM (2010)
   Comment on the Importance of S100A4 in regulation of MMP-13
   J Biol Chem, 285 (53), le23; author reply le24
   DOI 10.1074/jbc.L110.125898, PubMed 21186294
2. Berge G, Costea DE, Berg M, Rasmussen H, Grotterød I, Lothe RA, Mælandsmo GM, Flatmark K (2010)
   Coexpression and nuclear colocalization of metastasis-promoting protein S100A4 and p53 without mutual regulation in colorectal carcinoma
   Amino Acids, 41 (4), 875-84
   DOI 10.1007/s00726-010-0514-6, PubMed 20191297
3. Berge G, Mælandsmo GM (2010)
   Evaluation of potential interactions between the metastasis-associated protein S100A4 and the tumor suppressor protein p53
   Amino Acids, 41 (4), 863-73
   DOI 10.1007/s00726-010-0497-3, PubMed 20177948
4. Boye K, Nesland JM, Sandstad B, Mælandsmo GM, Flatmark K (2010)
   Nuclear S100A4 is a novel prognostic marker in colorectal cancer
   Eur J Cancer, 46 (16), 2919-25
   DOI 10.1016/j.ejca.2010.07.013, PubMed 20719498
5. Grotterød I, Maelandsmo GM, Boye K (2010)
   Signal transduction mechanisms involved in S100A4-induced activation of the transcription factor NF-kappaB
   BMC Cancer, 10, 241
   DOI 10.1186/1471-2407-10-241, PubMed 20507646
6. Oy GF, Slipicevic A, Davidson B, Solberg Faye R, Maelandsmo GM, Flørenes VA (2010)
   Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma
   Int J Cancer, 126 (2), 350-61
   DOI 10.1002/ijc.24727, PubMed 19588500
7. Prasmickaite L, Engesaeter BØ, Skrbo N, Hellenes T, Kristian A, Oliver NK, Suo Z, Maelandsmo GM (2010)
   Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma
   PLoS One, 5 (5), e10731
   DOI 10.1371/journal.pone.0010731, PubMed 20505780
8. Prasmickaite L, Skrbo N, Høifødt HK, Suo Z, Engebråten O, Gullestad HP, Aamdal S, Fodstad Ø, Maelandsmo GM (2010)
   Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells
   Pigment Cell Melanoma Res, 23 (3), 449-51
   DOI 10.1111/j.1755-148X.2010.00690.x, PubMed 20236249
9. Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K (2010)
   Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
   Lancet Oncol, 11 (5), 459-64
   DOI 10.1016/S1470-2045(10)70058-9, PubMed 20378407

Publications 2009

1. Boye K, Maelandsmo GM (2009)
   S100A4 and metastasis: a small actor playing many roles
   Am J Pathol, 176 (2), 528-35
   DOI 10.2353/ajpath.2010.090526, PubMed 20019188
2. Engebraaten O, Trikha M, Juell S, Garman-Vik S, Fodstad Ø (2009)
   Inhibition of in vivo tumour growth by the blocking of host alpha(v)beta3 and alphaII(b)beta3 integrins
   Anticancer Res, 29 (1), 131-7
   PubMed 19331142
3. Hoyem S, Bruheim S, Maelandsmo G, Standal M, Olberg DE, Brudeli B, Asberg A, Klaveness J, Rongved P (2009)
   Didanosine ester prodrugs: Synthesis, albumin binding properties and pharmacokinetic studies in rats (vol 44, pg 3874, 2009)
   Eur. J. Med. Chem., 44 (11), 4786
4. Maelandsmo GM, Flørenes VA, Nguyen MT, Flatmark K, Davidson B (2009)
   Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites
   Tumour Biol, 30 (1), 15-25
   DOI 10.1159/000199447, PubMed 19194111

Publications 2008

1. Boye K, Grotterød I, Aasheim HC, Hovig E, Maelandsmo GM (2008)
   Activation of NF-kappaB by extracellular S100A4: analysis of signal transduction mechanisms and identification of target genes
   Int J Cancer, 123 (6), 1301-10
   DOI 10.1002/ijc.23617, PubMed 18548584
2. Haugen MH, Flatmark K, Mikalsen SO, Malandsmo GM (2008)
   The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications
   BMC Cancer, 8, 172
   DOI 10.1186/1471-2407-8-172, PubMed 18554396
3. Ree AH (2008)
   Highly proliferative neuroendocrine carcinoma - influence of radiotherapy fractionation on tumor response
   Radiat Oncol, 3, 13
   DOI 10.1186/1748-717X-3-13, PubMed 18489745
4. Ree AH, Bratland A, Dueland S (2008)
   [Molecular targeted therapy in colorectal cancer]
   Tidsskr Nor Laegeforen, 128 (2), 190-3
   PubMed 18202731
5. Ree AH, Folkvord S, Flatmark K (2008)
   HDAC2 deficiency and histone acetylation
   Nat Genet, 40 (7), 812-3; author reply 813
   DOI 10.1038/ng0708-812, PubMed 18583969

Publications 2007

1. Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O (2007)
   Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines
   J Gene Med, 9 (6), 440-51
   DOI 10.1002/jgm.1036, PubMed 17410615

Publications 2006

1. Boye K, Andersen K, Tveito S, Øyjord T, Maelandsmo GM (2006)
   Interferon-gamma-induced suppression of S100A4 transcription is mediated by the class II transactivator
   Tumour Biol, 28 (1), 27-35
   DOI 10.1159/000097700, PubMed 17143014
2. Engesaeter BØ, Bonsted A, Lillehammer T, Engebraaten O, Berg K, Maelandsmo GM (2006)
   Photochemically mediated delivery of AdhCMV-TRAIL augments the TRAIL-induced apoptosis in colorectal cancer cell lines
   Cancer Biol Ther, 5 (11), 1511-20
   DOI 10.4161/cbt.5.11.3301, PubMed 17012835
3. Engesaeter BØ, Tveito S, Bonsted A, Engebraaten O, Berg K, Maelandsmo GM (2006)
   Photochemical treatment with endosomally localized photosensitizers enhances the number of adenoviruses in the nucleus
   J Gene Med, 8 (6), 707-18
   DOI 10.1002/jgm.902, PubMed 16518880
4. Ree AH (2006)
   A complex case of rectal neuroendocrine carcinoma with terminal delirium
   Nat Clin Pract Gastroenterol Hepatol, 3 (7), 408-13; quiz 414
   DOI 10.1038/ncpgasthep0525, PubMed 16819503
5. Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
   DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
   Anticancer Res, 26 (3A), 1909-16
   PubMed 16827124

Publications 2005

1. Engesaeter BØ, Bonsted A, Berg K, Høgset A, Engebråten O, Fodstad Ø, Curiel DT, Maelandsmo GM (2005)
   PCI-enhanced adenoviral transduction employs the known uptake mechanism of adenoviral particles
   Cancer Gene Ther, 12 (5), 439-48
   DOI 10.1038/sj.cgt.7700808, PubMed 15678152
2. Lillehammer T, Tveito S, Engesaeter BO, Fodstad O, Maelandsmo GM, Engebraaten O (2005)
   Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers
   Cancer Gene Ther, 12 (11), 864-72
   DOI 10.1038/sj.cgt.7700852, PubMed 15891771
3. Maelandsmo GM, Ross PJ, Pavliv M, Meulenbroek RA, Evelegh C, Muruve DA, Graham FL, Parks RJ (2005)
   Use of a murine secreted alkaline phosphatase as a non-immunogenic reporter gene in mice
   J Gene Med, 7 (3), 307-15
   DOI 10.1002/jgm.666, PubMed 15515146

Publications 2004

1. Andersen K, Nesland JM, Holm R, Flørenes VA, Fodstad Ø, Maelandsmo GM (2004)
   Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma
   Mod Pathol, 17 (8), 990-7
   DOI 10.1038/modpathol.3800151, PubMed 15133476
2. Prasmickaite L, Høgset A, Olsen VM, Kaalhus O, Mikalsen SO, Berg K (2004)
   Photochemically enhanced gene transfection increases the cytotoxicity of the herpes simplex virus thymidine kinase gene combined with ganciclovir
   Cancer Gene Ther, 11 (7), 514-23
   DOI 10.1038/sj.cgt.7700720, PubMed 15118758
3. Ree AH, Bratland A, Nome RV, Stokke T, Fodstad O, Andersson Y (2004)
   Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?
   Radiother Oncol, 72 (3), 305-10
   DOI 10.1016/j.radonc.2004.07.002, PubMed 15450729
4. Ree AH, Bratland A, Solberg Landsverk K, Fodstad O (2004)
   Ionizing radiation inhibits the PLK cell cycle gene in a G2 checkpoint-dependent manner
   Anticancer Res, 24 (2B), 555-62
   PubMed 15160994

Publications 2003

1. Andersen K, Smith-Sørensen B, Pedersen KB, Hovig E, Myklebost O, Fodstad Ø, Maelandsmo GM (2003)
   Interferon-gamma suppresses S100A4 transcription independently of apoptosis or cell cycle arrest
   Br J Cancer, 88 (12), 1995-2001
   DOI 10.1038/sj.bjc.6600998, PubMed 12799648
2. Maelandsmo GM, Holm R, Nesland JM, Fodstad Ø, Flørenes VA (2003)
   Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma
   Clin Cancer Res, 9 (9), 3383-8
   PubMed 12960126
3. Ree AH, Bratland A, Nome RV, Stokke T, Fodstad Ø (2003)
   Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1
   Oncogene, 22 (55), 8952-5
   DOI 10.1038/sj.onc.1207000, PubMed 14654792

Publications 2002

1. Engebraaten O, Hjortland GO, Juell S, Hirschberg H, Fodstad O (2002)
   Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals
   Int J Cancer, 97 (6), 846-52
   DOI 10.1002/ijc.10137, PubMed 11857366
2. Pedersen KB, Nesland JM, Fodstad Ø, Maelandsmo GM (2002)
   Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies
   Br J Cancer, 87 (11), 1281-6
   DOI 10.1038/sj.bjc.6600624, PubMed 12439718
3. Prasmickaite L, Høgset A, Berg K (2002)
   Photochemical transfection. Light-induced, site-directed gene delivery
   Methods Mol Med, 69, 123-35
   DOI 10.1385/1-59259-141-8:123, PubMed 11987772
4. Prasmickaite L, Høgset A, Berg K (2002)
   The role of the cell cycle on the efficiency of photochemical gene transfection
   Biochim Biophys Acta, 1570 (3), 210-8
   DOI 10.1016/s0304-4165(02)00202-7, PubMed 12020812
5. Prasmickaite L, Høgset A, Selbo PK, Engesaeter BØ, Hellum M, Berg K (2002)
   Photochemical disruption of endocytic vesicles before delivery of drugs: a new strategy for cancer therapy
   Br J Cancer, 86 (4), 652-7
   DOI 10.1038/sj.bjc.6600138, PubMed 11870551
6. Ree AH, Bratland A, Kroes RA, Aasheim HC, Flørenes VA, Moskal JR, Fodstad O, Bruland OS, Maelandsmo GM (2002)
   Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases
   Anticancer Res, 22 (4), 1949-57
   PubMed 12174869
7. Ree AH, Engebraaten O, Hovig E, Fodstad Ø (2002)
   Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: gene expression profiles in bone marrow target cells
   Int J Cancer, 97 (1), 28-33
   DOI 10.1002/ijc.1564, PubMed 11774240

Publications 2001

1. Prasmickaite L, Høgset A, Berg K (2001)
   Evaluation of different photosensitizers for use in photochemical gene transfection
   Photochem Photobiol, 73 (4), 388-95
   DOI 10.1562/0031-8655(2001)073<0388:eodpfu>2.0.co;2, PubMed 11332034

Publications 2000

1. Engebraaten O, Sivam G, Juell S, Fodstad O (2000)
   Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats
   Int J Cancer, 88 (6), 970-6
   DOI 10.1002/1097-0215(20001215)88:6<970::aid-ijc21>3.0.co;2-q, PubMed 11093823
2. Prasmickaite L, Høgset A, Tjelle TE, Olsen VM, Berg K (2000)
   Role of endosomes in gene transfection mediated by photochemical internalisation (PCI)
   J Gene Med, 2 (6), 477-88
   DOI 10.1002/1521-2254(200011/12)2:6<477::AID-JGM137>3.0.CO;2-B, PubMed 11199268
3. Ree AH, Pacheco MM, Tvermyr M, Fodstad O, Brentani MM (2000)
   Expression of a novel factor, com1, in early tumor progression of breast cancer
   Clin Cancer Res, 6 (5), 1778-83
   PubMed 10815897
4. Vollestad LA, Lillehammer T (2000)
   Individual variation in early life-history traits in brown trout
   Ecol. Freshw. Fish, 9 (4), 242-247

Publications 1999

1. Engebraaten O, Fodstad O (1999)
   Site-specific experimental metastasis patterns of two human breast cancer cell lines in nude rats
   Int J Cancer, 82 (2), 219-25
   DOI 10.1002/(sici)1097-0215(19990719)82:2<219::aid-ijc12>3.0.co;2-#, PubMed 10389756
2. Engebraaten O, Hjortland GO, Hirschberg H, Fodstad O (1999)
   Growth of precultured human glioma specimens in nude rat brain
   J Neurosurg, 90 (1), 125-32
   DOI 10.3171/jns.1999.90.1.0125, PubMed 10413165
3. Ree AH, Hansson V, Walaas SI, Eskild W, Taskén KA (1999)
   Calcium/phospholipid-dependent protein kinases in rat Sertoli cells: regulation of androgen receptor messenger ribonucleic acid
   Biol Reprod, 60 (5), 1257-62
   DOI 10.1095/biolreprod60.5.1257, PubMed 10208993
4. Ree AH, Tvermyr M, Engebraaten O, Rooman M, Røsok O, Hovig E, Meza-Zepeda LA, Bruland OS, Fodstad O (1999)
   Expression of a novel factor in human breast cancer cells with metastatic potential
   Cancer Res, 59 (18), 4675-80
   PubMed 10493524

Publications 1998

1. Prasmickaite L, Hogset A, Maelandsmo G, Berg K, Goodchild J, Perkins T, Fodstad O, Hovig E (1998)
   Intracellular metabolism of a 2'-O-methyl-stabilized ribozyme after uptake by DOTAP transfection or asfree ribozyme. A study by capillary electrophoresis
   Nucleic Acids Res, 26 (18), 4241-8
   DOI 10.1093/nar/26.18.4241, PubMed 9722645
2. Ree AH, Bjørnland K, Brünner N, Johansen HT, Pedersen KB, Aasen AO, Fodstad O (1998)
   Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells
   Clin Exp Metastasis, 16 (3), 205-15
   DOI 10.1023/a:1006584624061, PubMed 9568638

Publications 1997

1. Maelandsmo GM, Flørenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O (1997)
   Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma
   Int J Cancer, 74 (4), 464-9
   DOI 10.1002/(sici)1097-0215(19970822)74:4<464::aid-ijc19>3.0.co;2-9, PubMed 9291441
2. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O (1997)
   High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases
   Clin Cancer Res, 3 (9), 1623-8
   PubMed 9815852

Publications 1996

1. Maelandsmo GM, Flørenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Børresen AL, Fodstad O (1996)
   Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas
   Br J Cancer, 73 (8), 909-16
   DOI 10.1038/bjc.1996.181, PubMed 8611425
2. Maelandsmo GM, Holm R, Fodstad O, Kerbel RS, Flørenes VA (1996)
   Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions
   Am J Pathol, 149 (6), 1813-22
   PubMed 8952518
3. Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Flørenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O (1996)
   Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme
   Cancer Res, 56 (23), 5490-8
   PubMed 8968106
4. Ree AH, Maelandsmo GM, Fodstad O (1996)
   Regulation of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in MCF-7 cells: comparison with regulatory mechanisms of pS2 expression
   Clin Exp Metastasis, 14 (4), 381-8
   DOI 10.1007/BF00123397, PubMed 8878412

Publications 1995

1. Maelandsmo GM, Berner JM, Flørenes VA, Forus A, Hovig E, Fodstad O, Myklebost O (1995)
   Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1
   Br J Cancer, 72 (2), 393-8
   DOI 10.1038/bjc.1995.344, PubMed 7640224

Publications 1993

1. ANDREASSEN A, BORRESEN AL, OYJORD T, SOLHEIM OP, FLORENES VA, BRULAND O, MYKLEBOST O, HOIE J, FODSTAD O (1993)
   CHROMOSOME-17P ABERRATIONS AND P53 EXPRESSION IN HUMAN SARCOMAS
   FRONTIERS OF OSTEOSARCOMA RESEARCH: INTERDISCIPLINARY SURVEY OF CLINICAL AND RESEARCH ADVANCES, 419-422
2. Engebråten O (1993)
   [Hypoplastic left heart syndrome]
   Tidsskr Nor Laegeforen, 113 (30), 3770-1
   PubMed 8278970